We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
The Zacks Analyst Blog Highlights Berkshire Hathaway, The Walt Disney, CVS Health, Citigroup and Canadian National Railway
Read MoreHide Full Article
For Immediate Release
Chicago, IL – July 12, 2022 – Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include: Berkshire Hathaway Inc. (BRK.B - Free Report) , The Walt Disney Co. (DIS - Free Report) , CVS Health Corp. (CVS - Free Report) , Citigroup Inc. (C - Free Report) , and Canadian National Railway Co. (CNI - Free Report) .
Here are highlights from Monday’s Analyst Blog:
Top Research Reports for Berkshire Hathaway, Walt Disney and CVS
The Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily features new research reports on 16 major stocks, including Berkshire Hathaway Inc., The Walt Disney Co. and CVS Health Corp.. These research reports have been hand-picked from the roughly 70 reports published by our analyst team today.
Berkshire Hathaway shares have outperformed the Zacks Insurance - Property and Casualty industry over the past year (+0.3% vs. -5.0%). The Zacks analyst believes that Berkshire's inorganic growth story remains impressive with strategic acquisitions.
A strong cash position supports earnings-accretive bolt-on buyouts and indicates the company's financial flexibility. Continued insurance business growth fuels increase in float, drive earnings and generates maximum return on equity. The non-insurance businesses are delivering improved results with increased revenues over the past few years. A sturdy capital level provides further impetus.
However, exposure to catastrophe loss induces earnings volatility and also affects the property and casualty underwriting results of Berkshire. Huge capital expenditures remain a headwind for the company.
Walt Disney shares have declined -38.1% over the year to date period against the Zacks Media Conglomerates industry's decline of -32.0%. The Zacks analyst believes that Disney+'s profitability is expected to be negatively impacted by higher investments in content, which will drive up programming and production costs at Media and Entertainment Distribution. Closure of its Asian theme park due to COVID-19 doesn't bode well for the Parks, Experiences and Products top-line growth.
Nevertheless, the company benefits from the growing popularity of Disney+, owing to a strong content portfolio and a cheaper bundle offering. Availability in the Nordics, Latin America and other Asian territories is helping it in expanding its user base. Revival in Parks business also holds promise in the long haul.
CVS Health shares have outperformed the Zacks Retail - Pharmacies and Drug Stores industry over the past year (+17.7% vs. +4.9%). The Zacks analyst believes that the company's continued investments to address housing insecurities and enhance access to health care services in underserved communities seem encouraging.
The raised earnings per share (EPS) guidance for 2022 buoys optimism. In fact, CVS Health exited the first quarter of 2022 with earnings and revenues beating the Zacks Consensus Estimate.
Yet, the contraction of margins on escalating costs does not bode well. The decline in operating profit due to the pending litigation with the state of Florida to settle all opioid claims against CVS Health raises apprehension.
Other noteworthy reports we are featuring today include Citigroup Inc., and Canadian National Railway Co..
Why Haven't You Looked at Zacks' Top Stocks?
Our 5 best-performing strategies have blown away the S&P's impressive +28.8% gain in 2021. Amazingly, they soared +40.3%, +48.2%, +67.6%, +94.4%, and +95.3%. Today you can access their live picks without cost or obligation.
Past performance is no guarantee of future results. Inherent in any investment is the potential for loss. This material is being provided for informational purposes only and nothing herein constitutes investment, legal, accounting or tax advice, or a recommendation to buy, sell or hold a security. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. It should not be assumed that any investments in securities, companies, sectors or markets identified and described were or will be profitable. All information is current as of the date of herein and is subject to change without notice. Any views or opinions expressed may not reflect those of the firm as a whole. Zacks Investment Research does not engage in investment banking, market making or asset management activities of any securities. These returns are from hypothetical portfolios consisting of stocks with Zacks Rank = 1 that were rebalanced monthly with zero transaction costs. These are not the returns of actual portfolios of stocks. The S&P 500 is an unmanaged index. Visit https://www.zacks.com/performance for information about the performance numbers displayed in this press release.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
The Zacks Analyst Blog Highlights Berkshire Hathaway, The Walt Disney, CVS Health, Citigroup and Canadian National Railway
For Immediate Release
Chicago, IL – July 12, 2022 – Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include: Berkshire Hathaway Inc. (BRK.B - Free Report) , The Walt Disney Co. (DIS - Free Report) , CVS Health Corp. (CVS - Free Report) , Citigroup Inc. (C - Free Report) , and Canadian National Railway Co. (CNI - Free Report) .
Here are highlights from Monday’s Analyst Blog:
Top Research Reports for Berkshire Hathaway, Walt Disney and CVS
The Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily features new research reports on 16 major stocks, including Berkshire Hathaway Inc., The Walt Disney Co. and CVS Health Corp.. These research reports have been hand-picked from the roughly 70 reports published by our analyst team today.
You can see all of today's research reports here >>>
Berkshire Hathaway shares have outperformed the Zacks Insurance - Property and Casualty industry over the past year (+0.3% vs. -5.0%). The Zacks analyst believes that Berkshire's inorganic growth story remains impressive with strategic acquisitions.
A strong cash position supports earnings-accretive bolt-on buyouts and indicates the company's financial flexibility. Continued insurance business growth fuels increase in float, drive earnings and generates maximum return on equity. The non-insurance businesses are delivering improved results with increased revenues over the past few years. A sturdy capital level provides further impetus.
However, exposure to catastrophe loss induces earnings volatility and also affects the property and casualty underwriting results of Berkshire. Huge capital expenditures remain a headwind for the company.
(You can read the full research report on Berkshire Hathaway here >>>)
Walt Disney shares have declined -38.1% over the year to date period against the Zacks Media Conglomerates industry's decline of -32.0%. The Zacks analyst believes that Disney+'s profitability is expected to be negatively impacted by higher investments in content, which will drive up programming and production costs at Media and Entertainment Distribution. Closure of its Asian theme park due to COVID-19 doesn't bode well for the Parks, Experiences and Products top-line growth.
Nevertheless, the company benefits from the growing popularity of Disney+, owing to a strong content portfolio and a cheaper bundle offering. Availability in the Nordics, Latin America and other Asian territories is helping it in expanding its user base. Revival in Parks business also holds promise in the long haul.
(You can read the full research report on Walt Disney here >>>)
CVS Health shares have outperformed the Zacks Retail - Pharmacies and Drug Stores industry over the past year (+17.7% vs. +4.9%). The Zacks analyst believes that the company's continued investments to address housing insecurities and enhance access to health care services in underserved communities seem encouraging.
The raised earnings per share (EPS) guidance for 2022 buoys optimism. In fact, CVS Health exited the first quarter of 2022 with earnings and revenues beating the Zacks Consensus Estimate.
Yet, the contraction of margins on escalating costs does not bode well. The decline in operating profit due to the pending litigation with the state of Florida to settle all opioid claims against CVS Health raises apprehension.
(You can read the full research report on CVS here >>>)
Other noteworthy reports we are featuring today include Citigroup Inc., and Canadian National Railway Co..
Why Haven't You Looked at Zacks' Top Stocks?
Our 5 best-performing strategies have blown away the S&P's impressive +28.8% gain in 2021. Amazingly, they soared +40.3%, +48.2%, +67.6%, +94.4%, and +95.3%. Today you can access their live picks without cost or obligation.
See Stocks Free >>
Media Contact
Zacks Investment Research
800-767-3771 ext. 9339
support@zacks.com
https://www.zacks.com
Past performance is no guarantee of future results. Inherent in any investment is the potential for loss. This material is being provided for informational purposes only and nothing herein constitutes investment, legal, accounting or tax advice, or a recommendation to buy, sell or hold a security. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. It should not be assumed that any investments in securities, companies, sectors or markets identified and described were or will be profitable. All information is current as of the date of herein and is subject to change without notice. Any views or opinions expressed may not reflect those of the firm as a whole. Zacks Investment Research does not engage in investment banking, market making or asset management activities of any securities. These returns are from hypothetical portfolios consisting of stocks with Zacks Rank = 1 that were rebalanced monthly with zero transaction costs. These are not the returns of actual portfolios of stocks. The S&P 500 is an unmanaged index. Visit https://www.zacks.com/performance for information about the performance numbers displayed in this press release.